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The nucleoside hydrolase (NH) of Leishmania donovani (NH36) is a phylogenetic marker of
high homology among Leishmania parasites. In mice and dog vaccination, NH36 induces
a CD4+ T cell-driven protective response against Leishmania chagasi infection directed
against its C-terminal domain (F3). The C-terminal and N-terminal domain vaccines also
decreased the footpad lesion caused by Leishmania amazonensis. We studied the basis of
the crossed immune response using recombinant generated peptides covering the whole
NH36 sequence and saponin for mice prophylaxis against L. amazonensis. The F1 (amino
acids 1–103) and F3 peptide (amino acids 199–314) vaccines enhanced the IgG and IgG2a
anti-NH36 antibodies to similar levels.The F3 vaccine induced the strongest DTH response,
the highest proportions of NH36-specific CD4+ and CD8+ T cells after challenge and
the highest expression of IFN-γ and TNF-α. The F1 vaccine, on the other hand, induced
a weaker but significant DTH response and a mild enhancement of IFN-γ andTNF-α levels.
The in vivo depletion with anti-CD4 or CD8 monoclonal antibodies disclosed that cross-
protection against L. amazonensis infection was mediated by a CD4+ T cell response
directed against the C-terminal domain (75% of reduction of the size of footpad lesion) fol-
lowed by a CD8+T cell response against the N-terminal domain of NH36 (57% of reduction
of footpad lesions). Both vaccines were capable of inducing long-term cross-immunity.The
amino acid sequence of NH36 showed 93% identity to the sequence of the NH A34480
of L. amazonensis, which also showed the presence of completely conserved predicted
epitopes for CD4+ and CD8+ T cells in F1 domain, and of CD4+ epitopes differing by a
single amino acid, in F1 and F3 domains.The identification of the C-terminal and N-terminal
domains as the targets of the immune response to NH36 in the model of L. amazonensis
infection represents a basis for the rationale development of a bivalent vaccine against
leishmaniasis.
Keywords: visceral leishmaniasis, cutaneous leishmaniasis, diffuse cutaneous leishmaniasis, cross-protection,
prophylaxis, nucleoside hydrolases, recombinant vaccines
INTRODUCTION
Leishmaniasis is considered a severe public health problem with
12 million people currently infected, 350 million at risk (1, 2), and
4 clinical syndromes due to different Leishmania species: cuta-
neous (CL) (3–5), diffuse (DCL) (3), mucocutaneous (MCL), and
visceral (VL). A bivalent vaccine that could generate protective
immunity to the agents of the visceral and cutaneous syndromes
would be economic and useful for the control of leishmaniasis
(6) in countries where both diseases are endemic. First, sec-
ond, and third generation vaccines have been developed against
leishmaniasis (7, 8). Among the vaccines tested in the field, most
are crude parasite vaccines against CL, with or without adjuvants
(9, 10) that induced a maximum of 50% vaccine efficacy (9). The
recombinant Leish-111f vaccine, on the other hand, was useful in
the immunotherapy and immunochemotherapy of patients with
CL and MCL (8) and in prophylaxis (11) but not in the therapy of
canine VL (12). No human vaccine is available against VL.
The Leishmune® veterinary vaccine against canine VL (13–
16) contributed to the reduction of the incidence of the human
and canine diseases (17). Its main component is the nucleoside
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hydrolase (NH) of Leishmania donovani (NH36) (18, 19). NHs
release purines and pyrimidines from imported nucleosides, allow
the synthesis of parasite DNA and its replication (20, 21) and are
mandatory at the early infection. NH36 is a powerful antigen (22),
a marker of the Leishmania genus (23, 24), which shows high
homology to the sequences of NHs of other Leishmania species
(25, 26), being thus a good candidate for a cross-protective bivalent
Leishmania vaccine.
NH36 protected mice from L. donovani infection (27) and
was identified among Leishmania major exo-antigens (28). As a
genetic vaccine, it induced a TH1 immune response mediated by
IFN-γ-producing CD4+ T cells (29) effective in mice prophy-
laxis against VL (30) and CL (28–31) and in mice (32) and dog
immunotherapy againstVL (33) indicating its potential use against
both leishmaniasis.
Three recombinant peptides of NH36 representing the amino
acids 1–103 (F1, N-terminal domain), 104–198 (F2, central
domain), and 199–314 (F3, C-terminal domain) respectively, were
generated and used to vaccinate mice (34). Protection against
Leishmania chagasi was related to the C-terminal domain and
was mainly mediated by a CD4+ T cell-driven response with a
lower contribution of CD8+ T cells (34). Preliminary results indi-
cated that, on other hand, both the C- and N-terminal domains
determined the reduction of the size of footpad lesions of mice
challenged with Leishmania amazonensis (34).
In this investigation, we aimed to study the cross-immunity
generated by the peptide domains of NH36 of L. donovani used
for prophylactic vaccination of mice against L. amazonensis. In
order to study the generation of the humoral and cellular immune
responses responsible for and to identify in this way, the immuno-
genic domains of NH36, which should be included in a potential
future bivalent vaccine against VL and CL. We identified that the
cross-protective efficacy responsible for protection against L. ama-
zonensis was related to epitopes for CD4+T cells of the C-terminal
and epitopes for CD8+ T cells of the N-terminal domains of the
NH, NH36.
MATERIALS AND METHODS
ETHICAL STATEMENTS
All mouse studies followed the guidelines set by the National
Institute of Health, USA, the EU Directive 2010/63/EU, and the
Institutional Animal Care and Use Committee approved the ani-
mal protocols (Biophysics Institute-UFRJ, Brazil, and protocol
IMPPG-007). All procedures and euthanasia were performed
under CO2 anesthesia, and all efforts were made to minimize
suffering.
RECOMBINANT PEPTIDES OF THE NH36 NUCLEOSIDE HYDROLASE OF
LEISHMANIA DONOVANI AND HOMOLOGY TO NH OF LEISHMANIA
AMAZONENSIS
NH36 is composed of 314 amino acids (EMBL, GenBank™, and
DDJB data bases, access number AY007193). Three fragments
of the NH36 antigen composed, respectively, of the amino acid
sequences 1–103 (F1), 104–198 (F2), and 199–314 (F3) were
cloned in the pET28b plasmid system (34) (Patent: INPI Brazil
PI 1015788-3.PCT/BR2011/000411) and expressed in Escherichia
coli Bl21DE3 cells and purified in a Ni-NTA column (Qiagen).
The fractions containing highly purified recombinant protein were
extensively dialyzed against PBS buffer and stored at −80°C. To
improve protein expression, F2 was further cloned in the pET28a
(34). For homology analysis, we used the sequence of L. amazonen-
sis NH A34480 (Scaffold1680 15191–16135) (35). The sequence
alignment was obtained using the BLASTP of the GenBank.
PROPHYLACTIC IMMUNIZATION, PARASITE CHALLENGE BY
L. AMAZONENSIS, AND ASSESSMENT OF PROTECTION
Eight-week-old female Balb/c mice were vaccinated three times
with 100µg of NH36, F1, F2, or F3 recombinant proteins and
100µg of SIGMA saponin (NH36sap, F1sap, F2sap, and F3sap
vaccines, respectively) at weekly intervals, by the sc route. At week
4, mice were challenged in the right hind footpad with 105 L.
amazonensis (PH 8 strain) metacyclic promastigotes (31), which
had been isolated from hamsters and maintained in Schneider’s
axenic media supplemented with 10% fetal calf serum for one
passage. The infected footpad thicknesses were measured weekly
with a Mitutoyo apparatus and the thickness values of the non-
infected left footpads were subtracted from them at each measure.
Seven days after immunization and 6 weeks after infection, sera
were collected for the anti-NH36 antibody assays and the intra-
dermal response against L. amazonensis lysate (IDR) was mea-
sured in the footpads. Mice were sacrificed 6 weeks after challenge
by euthanasia with carbon dioxide. The cellular immunity was
assessed by flow cytometry analysis (FACS analysis), intracellu-
lar staining (ICS) of splenocytes, and cytokine-ELISA assays of
splenocyte supernatants. For the assessment of long-term immu-
nity, mice received the same immunization protocol but were
challenged 1 month after the last vaccine dose. In these animals,
cross-protection was evaluated by monitoring the sizes of foot-
pad lesions and by determination of the parasite load in lesions
after euthanasia by a limiting dilution assay as modified from de
Oliveira Cardoso et al. (36).
DETECTION OF ANTIBODIES
Antibodies were measured in sera using an ELISA assay against
NH36 recombinant proteins as previously described (34). The
ELISA assay used 2µg of NH36 per well (50µl of a 40µg/ml anti-
gen solution) and goat anti-mouse IgG (Sigma) or goat anti-mouse
IgG1, IgG2a, IgG2b, IgG3, IgM, and IgA horseradish peroxidase
conjugated antibodies (Southern, Biotechnology Associates, Birm-
ingham, AL, USA) in a 1:1000 dilution in the blocking buffer. The
reaction was developed with O-phenyldiamine (Sigma), inter-
rupted with 1 N sulfuric acid, and monitored at 492ηm. Each
individual serum was analyzed in triplicate in double-blind tests.
Positive and negative control sera were included in each test.
Results were expressed as the mean of the absorbance values
(492ηm) of the 1/100 diluted sera of each animal.
ANALYSIS OF THE CELLULAR IMMUNITY
Intradermal response to leishmanial antigen (IDR)
The intradermal response against L. amazonensis lysate (IDR) was
measured in the footpads. Briefly, mice were injected intrader-
mally, in the right front footpad, with 107 freeze-thawed station-
ary phase L. amazonensis promastigotes in 0.1 ml sterile saline
solution. The parasites were obtained as amastigotes aseptically
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removed from L. amazonensis (PH 8 strain) infected hamster
footpad lesions, transformed, and cultured in Schneider’s axenic
medium at 26°C until they reached the stationary phase of growth
and were then disrupted by three consecutive freeze-and-thaw
cycles using liquid Nitrogen. The footpad thicknesses were mea-
sured with a Mitutoyo apparatus, both before and at 0, 24, and 48 h
after injection. Injecting each animal with 0.1 ml saline in the left
front footpad served as control. At each measurement, the values
of the saline control were subtracted from the reaction due to the
Leishmania antigen.
Anti-NH36-specific T cell immunity
Spleens were aseptically removed and disrupted in NaCl saline
solution (Sigma Co., USA) using a Petri dish and nylon mesh,
suspended to 11 ml with lysis solution (NH4Cl 8.29 g/l, KHCO3
1 g/l, and EDTA 37.2 mg/l) and further centrifuged at 400×g for
5 min at 4°C until total red blood cell removal. The pellet was
further washed with saline solution by centrifugation, incubated
with 3 ml RPMI supplemented with 10% fetal calf serum, 0.05 mM
2-mercaptoethanol and antibiotics (200 U/ml of penicillin and
200µg/ml of streptomycin), counted in a hemocytometer cham-
ber. For cytokine dosage, splenocytes were distributed in 96 well
flat-bottomed plates (Nunc, Roskilde, Denmark) with each well
containing 106 cells in a final volume of 200µl and incubated,
in the presence or absence of 5µg of recombinant NH36 for
3 days at 37°C under a 5% CO2 atmosphere. RPMI supplemented
medium was added as negative control. After this period, super-
natants were harvested, centrifuged at 14,000 rpm for 11 s, and
further stored at −70°C until dosage. Secretion of IFN-γ, TNF-α,
and IL-10 was evaluated in the supernatants by an ELISA assay,
using the mouse IFN-γ, TNF-α, and IL-10 BD OptEIA ELISA Set
II kits (BD Bioscience) according to the manufacturer’s instruc-
tions. Splenocytes, after in vitro incubation, were processed for
immunostaining with anti-CD4 (clone GK1.5) or anti-CD8-FITC
(clone 53-6.7) monoclonal antibodies (R&D systems Inc.) and
analyzed by flow cytometry analysis (FACS analysis) in a FACScal-
ibur apparatus. Cells were analyzed by flow cytometry in a Becton
Dickinson FACScalibur apparatus. Data were analyzed using the
Win MDI program.
In vivo depletion of CD4+ or CD8+ T cells
Mice were vaccinated with three doses of F1sap and F3sap at
weekly intervals were challenged with 105 L. amazonensis infec-
tive promastigotes, 10 days after complete vaccination. One week
after complete vaccination and on week 6 after challenge, the IDR
against L. amazonensis lysate was assayed. In vivo depletion was
performed by treating groups of F1- and F3-vaccinated mice with
GK1.5 or 53.6.7 rat IgG MAb on days 2, 4, and 6 before chal-
lenge and on day 14 after challenge. Mice were treated with 50µl
of ascitic fluid containing an approximate 5 mg/ml MAb concen-
tration. Control mice received the F1sap or F3sap vaccines and
0.05 mL of rat serum ip, equivalent to 0.25 mg of IgG, or nude mice
ascitic fluids containing 0.25 mg of anti-CD4+ and/or anti-CD8+
antibodies. As determined by FACS analyses, the efficacy of deple-
tion of CD4+ or CD8+ spleen cells before challenge was of 99.94
or 96% in anti-CD4+ or anti-CD8+ treated mice, respectively.
The efficacy of depletion treatment was monitored by the increase
of the size of footpad lesions along the 6 weeks of experiment. In
addition, the parasite load in lesions on week 6 was evaluated by a
limiting dilution assay (36).
STATISTICAL ANALYSIS
Means were compared by Kruskall–Wallis and Mann–Whitney
non-parametrical tests. For the levels of IFN-γ and TNF-α induced
by the F1 vaccine, we also used the confidence interval (95% CI)
(Analyze-it). Correlation coefficient analysis was determined on a
Pearson bivariate, two tailed test of significance (GraphPad Prism
6). The values of R2, which represents the fraction of the total
variance in Y that can be explained by the variation in X, were
obtained using linear regression analysis (Analyze-it).
RESULTS
Mice were immunized with NH36, F1, F2, or F3 proteins and
saponin, challenged with infective promastigotes of L. amazonensis
at 4 weeks and euthanized 6 weeks after challenge. After immuniza-
tion (Figure 1A), the humoral response against the NH36 antigen
assayed by ELISA disclosed higher IgM, IgG, IgG1, and IgG2a anti-
body levels in the mice sera of all vaccines when compared to saline
controls (p< 0.001). The F3sap vaccine showed the best perfor-
mance, inducing IgG and IgG2a levels as high as NH36sap. Both
the F3 and the F1 vaccines induced similar levels of IgM to the
NH36 vaccine while the IgG2b was only enhanced by the NH36
and the IgG3 by the F1 vaccine, respectively (Figure 1A). After
challenge, significant differences were observed among IgG, IgG1,
IgG2a, IgG2b, and IgG3 antibodies (<0.001, for all antibody types)
(Figure 1B). While the NH36sap vaccine showed the highest levels
of IgG and IgG3 antibodies, the F3sap was as strong as the NH36
vaccine in the IgG1, IgG2a, IgG2b subtypes. Differently from what
FIGURE 1 | Development of NH36-specific humoral immune response.
Bars represent the mean±SE of the absorbance values of anti-NH36
antibodies from 1/100 diluted serum of three independent experiments
after immunization (n=3 mice per treatment in each experiment) (A) and
two independent experiments after challenge (n=7 mice per treatment in
each experiment) (B). *p<0.05 from the saline control; p<0.05 different
from the F2sap vaccine; p<0.05 different from F3sap.
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FIGURE 2 | Intradermal response to the leishmanial antigen, flow
cytometry analysis, and ELISA of cytokines in supernatants of mice
splenocytes. IDR after immunization (A) and after challenge (B) 24 h (left) and
48 h (right) after antigen injection. Splenocytes after in vitro culture for 3 days
at 37°C and 5% CO2 in the presence or absence of 5µg/ml of recombinant
NH36 and staining with anti-CD4 or anti-CD8 antibodies (C). Results of two
independent experiments with 9–10 mice per treatment group are shown as
mean±SE. *p<0.05 from the saline controls, • the F1, the F2, or from
all the other vaccines. Secretions of IFN-γ (D), TNF-α (E), and IL-10 (F) in the
supernatant of splenocytes, after challenge, are expressed in picogram per
milliliters. Horizontal bars represent the mean values of one experiment (four
to nine mice per treatment). *Significant differences between groups.
was seen before infection (Figure 1A), after challenge, the F1sap
and F3sap vaccines showed levels of IgG1 and IgG2a antibodies
significantly increased above the F2sap vaccine (Figure 1B).
The cell-mediated immune response induced by immunization
was initially assessed by the IDR to the L. amazonensis leishmanial
antigen that was higher in all vaccinated animals than in controls
prior to (Figure 2A) and after challenge (Figure 2B) (p< 0.0001
in both cases). After immunization, the F3sap vaccine induced
higher footpad swelling than the F1sap vaccine. After challenge,
the IDR responses were enhanced (p= 0.049 at 24 h and p= 0.007
at 48 h) mainly by the NH36sap, which was as potent as F3sap
vaccine at 24 h after injection (Figure 2B). The preponderance
of the F3sap vaccine was recovered 48 h after injection, when it
induced the strongest intradermal reaction (Figure 2B). The pro-
portions of anti-NH36-specific CD4+ and CD8+ lymphocytes in
spleens were analyzed by FACS (Figure 2C). After immunization,
the proportions of splenic CD4+ T cells of mice vaccinated with
NH36 vaccine were higher than those of the saline controls. After
challenge, and as expected for CL, the CD4+ proportions of saline
control were sustained and only the F3 vaccine showed signifi-
cantly increased proportions of NH36-specific CD4+ T cells over
those of the F2 vaccine and of NH36-specific CD8+ T cells over
the saline control (Figure 2C).
Six weeks after infection, the levels of cytokines were measured
in supernatants of 106 splenocytes after 3 days of in vitro culture
with the addition of 5µg of recombinant NH36. The results shown
in Figures 2D–F are already subtracted from the values obtained
without RPMI medium without antigen stimulation. Both the
NH36sap (mean= 1510.15 pg/ml) and the F3sap-vaccinated mice
(mean= 1888.85 pg/ml) showed higher concentrations of IFN-
γ (p< 0.01 for both vaccines) than the F2sap-vaccinated mice
(mean= 111.21 pg/ml) (Figure 2D). The TNF-α expression was
increased only by the F3sap vaccine (mean= 318.87 pg/ml) over
the saline controls (mean= 70.45 pg/ml) (p< 0.05) (Figure 2E)
while no differences were detected in the IL-10 expression
(Figure 2F). The secretion of IFN-γ and TNF-α was strongly cor-
related (p= 0.043). The levels of IFN-γ and TNF-α induced by
the F1 vaccine did not achieve a significant difference compared
to the F2 vaccine. However, the mean for IFN-γ (607.19 pg/ml)
of the F1sap group fell outside the CI95% of the F2sap group
(−221.17 to 332.39 pg/ml) (Figure 2D) and the mean for TNF-α
of the F1sap group (370.28 pg/ml) also fell outside the CI95%
of the F2sap group (77.44–77.52 pg/ml) (Figure 2E). No sig-
nificant differences were observed between the levels of IL-
10 generated by any treatment (Figure 2F). The supernatants
represented in Figures 2D–F correspond to the lymphocytes,
after challenge, represented in Figure 2C. At this point, lym-
phocytes represent 56.36% of the total splenocytes in culture
(43.70% average of CD4 T lymphocytes+ 12.66% average of CD8
T lymphocytes).
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FIGURE 3 | In vivo depletion assay with anti-CD4 and anti-CD8
monoclonal antibodies. Mice were challenged with L. amazonensis after
vaccination with F1sap (A) and F3sap (B) vaccines and treated with rat
serum, anti-CD4+ or anti-CD8+, or the combination of anti-CD4 and
anti-CD8 MAbs. Results are shown as the mean±SD of the footpad
measurements of one experiment (four to five animals per treatment) along
the time. *p<0.05, different from the F1sap (A) and F3sap (B) vaccines.
To detail the importance of CD4 and CD8+ epitopes of the F3
and F1 domains in cross-protection to L. amazonensis infection,
we performed an in vivo depletion assay with anti-CD4 and anti-
CD8+monoclonal antibodies using mice immunized with F1sap
and F3sap vaccines and challenged. The evolution of the sizes of
footpad lesions is summarized in Figure 3. Significant differences
among treatments were detected at week 6 (p< 0.0001). When
compared to saline control, the F1sap vaccine determined a 57%
(p= 0.008) reduction of footpad lesions that was not blocked by
the anti-CD4-Mab (p= 0.413) but that was abolished by treat-
ment with anti-CD8 antibody (p= 0.016) (Figure 3A). On the
other hand, when compared to the saline control, the F3sap vaccine
(Figure 3B) determined a 75% (p= 0.008) reduction in footpad
lesion that was blocked by anti-CD4+ antibodies (p= 0.016 com-
pared to the F3sap vaccine) but not impaired by depletion with
anti-CD8-Mab (p= 0.730 compared to the F3sap vaccine). Our
results indicate that the reduction of the size of lesion generated
by F1sap vaccine is mainly mediated by CD8 epitopes present
in the sequence of the F1 domain while reduction of lesion size
induced by the F3sap vaccine is related to the presence of CD4+
epitopes in the F3 domain.
This hypothesis was also supported by the analysis of IDR after
challenge, which disclosed significant differences among treat-
ments (p< 0.0001) both at 24 h (not shown) and 48 h after anti-
gen injection (Figure 4A). IDR was increased above the saline
controls, in mice vaccinated with F1sap (p< 0.008), treated or
not with anti-CD4+ Mab (p= 0.02), but it was decreased after
treatment with anti-CD8+ and both anti-CD4 and -CD8 antibod-
ies (Figure 4A) suggesting that the IDR response enhancement is
related to epitopes for CD8+ T cells located in the F1 domain.
The F3sap vaccine, showed a stronger IDR than the F1sap vac-
cine (p= 0.008) (Figure 4A), that was abolished by anti-CD4 Mab
but not anti-CD8 Mab suggesting that it was mainly mediated by
CD4+T cells with a partial contribution of CD8+T lymphocytes.
The size of footpad lesions on week 6 showed significant nega-
tive correlation to the results of intradermal response (R=−0.79;
p< 0.0001; R2= 0.63 for IDR 24 h; and R=−0.82; p< 0.0001;
R2= 0.68 for IDR at 48 h) confirming that IDR is a good correlate
of protection.
In correlation with these results, the parasite load in foot-
pad lesion, evaluated by a limiting dilution assay (Figure 4B),
also disclosed that protection induced by F1sap was abolished
in mice treated with anti-CD8 Mab (p= 0.032) while protec-
tion generated by the F3sap vaccine was absent in mice treated
with anti-CD4 Mab (p= 0.016). When compared to the saline
controls (514,850 promastigotes), 99.93% (513 promastigotes)
and 99.90% (341 promastigotes) reductions in the number of
parasites were determined by the F3 and the F1 vaccines, respec-
tively. The log10 values of parasite load in footpads correlated
significantly with the increase in IDR (R=−0.6734; p< 0.0001;
R2= 0.4534) and with the decrease in footpad lesions (R= 0.5994;
p< 0.0001; R2= 0.3593) confirming that NH36 vaccine generated
cross-protection against cutaneous leishmaniasis is determined by
CD8 epitopes of F1 domain and by CD4 epitopes in the F3 domain.
The secretion of IFN-γ (R=−0.5518; p= 0.002; R2= 0.3045)
and TNF-α (R=−0.4655; p= 0.011; R2= 0.2162) was nega-
tively correlated with the increase of footpads lesions sizes (not
shown) and thus, were strong correlates of protection against L.
amazonensis infection.
The superiority of the F3 over the NH36 vaccine was evident
in many variables. We calculated the increment in the immuno-
protective effect of the F3 vaccine taking into consideration all
the variables that showed significant differences between the two
formulations (Table 1). We found that the F3 vaccine developed a
40.40% higher average protective effect than the NH36 vaccine.
We further assessed the possible long-term cross-protection
generated by the F3sap and F1sap vaccines in Balb/c mice that
received three weekly interval vaccinations but that were chal-
lenged 1 month after the last vaccine dose. Significant reductions
in the sizes of footpad lesions were achieved by vaccination with
the F1sap (72%, p= 0.0003) and the F3sap vaccine (99.82%,
p= 0.0002). Six weeks after challenge, the F3 vaccine reduced the
lesions more than the F1 vaccine (p= 0.002) (Figure 5A). When
compared to the saline controls (p< 0.01), the limiting dilution
assay analysis disclosed also a 99.82% level of protection gener-
ated by the F3 vaccine (mean promastigotes= 757) followed by a
98.97% reduction (4531.25 promastigotes) due to the F1 vaccine
(Figure 5B). Parasite reduction was more pronounced in the F3
than in the F1 vaccine treated mice (p< 0.01).
The alignment of the amino acid sequences of L. donovani
NH36 and the recently identified, NH A34480 of L. amazonen-
sis, is represented in Figure 6. Both proteins are composed of 314
amino acids and show 93% of identity (292 from 314 amino acids)
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FIGURE 4 | Intradermal response and number of parasites in footpad
lesions of mice submitted to an in vivo depletion assay with anti-CD4
and anti-CD8 monoclonal antibodies. The IDR to Leishmania amazonensis
lysate was measured in F1sap- and F3sap-vaccinated animals that were
challenged with L. amazonensis and treated with rat serum, anti-CD4 or
anti-CD8, or the combination of anti-CD4+ and anti-CD8+MAbs (A). IDR was
measured 6 weeks after challenge and 48 h after antigen injection. Results of
one experiment with four to five mice per treatment group are shown.
*p<0.05, different from the saline controls and horizontal lines represent
significant differences between the two vaccines (A). In the limiting dilution
assay (B) bars represent the number of promastigotes±SD in each
treatment (one experiment with four to five mice per treatment). • Horizontal
lines express significant differences from the F1sap- or F3sap-vaccinated
treated with rat IgG only.
Table 1 | Superiority of the F3 peptide domains over the NH36 vaccine
in prophylaxis against L. amazonensis infection.
Variable F3 NH36 Enrichment (%)
IDR 48 h after challenge 0.290 0.210 27.58
INF-γ in supernatants 1888.85 1510.15 20.04
TNF-α in supernatants 322.47 284.95 11.64
Reduction of parasite load
L. amazonensis
16.60 1.156 93.03
Mean+SD 40.40+27.77
Calculation was performed according to the following equation= (F3−NH36/F3)
values×100=protective effect increment.
with no gaps. Additionally, we show the identity of the sequences
of the predicted epitopes for CD4+ and CD8+ T cells, in the F1
and F3 domains of both proteins (Figure 6). The first epitope for
CD4+ and the epitope for CD8+ T cells of the F1 domain of the
two Leishmanias are conserved showing total identity, while the
second epitope for CD4+ T cell shows a difference only in the
last amino acid. Indeed, Alanine (A) is present in L. amazonensis
NH instead of the final threonine (T) of NH36 of L. donovani.
Furthermore, a difference in only one amino acid was found in the
sequences of the three epitopes for CD4+ lymphocytes of the F3
domain. In the first CD4+ epitope, glutamine (Q) is exchanged
for glycine (G), in the second epitope, histidine (H) is substituted
by asparagine (N), and in the third epitope, lysine (K) is replaced
by glutamic acid (G) (Figure 6).
DISCUSSION
We were able to disclose the antigenic basis of NH36 of L. dono-
vani in cross-protection to infection by L. amazonensis. Our
results show that the global increase of the humoral and cel-
lular immune response promoted by the F3sap vaccine and the
increase of the antibody response, IFN-γ and TNF-α secretion by
the F1sap vaccine determined the vaccine protection against the
L. amazonensis challenge. We also demonstrated that the cellular
immune response induced by the F3 peptide (C-terminal domain)
against the L. amazonensis infection is superior to the one induced
by the cognate NH36 protein suggesting that it holds the main
NH36 sequences responsible for the TH1 immune response. The
increased IFN-γ and TNF-α secretion in supernatants confirmed
the predominance of the immunogenicity of the F3 peptide. On
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the other hand, the F1 vaccine induced a weaker but significant
DTH response and a mild enhancement of IFN-γ and TNF-α
levels.
FIGURE 5 | Long-term cross-protection generated by the F3sap and
F1sap vaccines. Balb/c mice were vaccinated with three doses of F1sap or
F3sap with a weekly interval and challenged with L. amazonensis infective
promastigotes, 30 days after the last immunization. The evolution of the
sizes of footpad lesions (A) and the parasite load in lesions (limiting dilution
assay) (B) were determined. Bars represent the mean±SD of one
experiment with 10 mice for each treatment. *p<0.05 significant
differences from the saline controls and ◦ from the F1sap vaccine.
In a previous work, we demonstrated that protection against L.
chagasi generated by the NH36 vaccine is related to its C-terminal
domain and is mediated mainly by a CD4+ T cell-driven response
with a lower contribution of CD8+ T cells (34). Increases in
IgM, IgG2a, IgG1, and IgG2b antibodies, CD4+ T cell propor-
tions, IFN-γ secretion, ratios of IFN-γ/IL-10 producing CD4+
and CD8+ T cells, and percents of antibody binding inhibition by
synthetic predicted epitopes were detected in F3-vaccinated mice.
The increases in DTH and in ratios of TNFα/IL-10 CD4+ produc-
ing cells were however the strong correlates of protection, which
was confirmed by in vivo depletion with monoclonal antibodies,
algorithm predicted CD4 and CD8 epitopes and a pronounced
decrease in parasite load (90.5–88.23%; p= 0.011) that was long-
lasting. No decrease in parasite load was detected after vaccination
with the N-domain of NH36, in spite of the induction of IFN-
γ/IL-10 expression by CD4+ T cells after challenge. Both peptides
reduced the size of footpad lesions, but only the C-domain reduced
the parasite load of mice challenged with L. amazonensis (34).
In the present study, as detected in the previous investigation
(34), the antibody response also indicated the predominance of
the F3 followed by the F1 peptide. This occurred, in the L. ama-
zonensis model, mainly after challenge. In the L. chagasi model
(34), the F3 was the only peptide to induce levels of IgG and
IgG2a antibodies as high as those of the NH36 vaccine. After L.
chagasi challenge, the IgG2a levels were 34% higher in the F3sap
than in the F1sap vaccine group. In the L. amazonensis model,
both F3 and F1 peptides seem to have similar degrees of con-
tribution to the humoral response. Antibodies to the F1 peptide
were also increased in infected dogs after immunotherapy with
the NH36 DNA vaccine (33). Coincidentally, two B cell epitopes
for dog and human antibodies were identified along the sequence
FIGURE 6 | Sequence analysis of nucleoside hydrolases of Leishmania
donovani and Leishmania amazonensis.The sequences of the
nucleoside hydrolases NH36 of L. donovani (Ld-NH36) and A34480 of
Leishmania amazonensis (La-NH) were aligned using the BLASTP
GenBank program. The line in the middle of the two sequences shows the
amino acids share by the two NHs. The peptide sequence of MHC class
II-IAd and -IEd, haplotype H2 CD4+T cell epitopes (34) are shown in black
squares, on the F1 and F3 fragments. The amino acid sequence of MHC
class I Ld-CD8+T cell predicted epitope of the F1 fragment (34) is
underlined in the gray square.
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of NH36 (37). Peptide 17 (TPAVQKRVKEVGTKP) (37) overlaps
with the epitope that we previously identified in the sequence of
F3 (AVQKRVKEVGTKPAAFML) (34), which was responsible for
the highest inhibition of antibody binding to NH36 (31.40%).
Peptide 18 (TTVVGNQTLEKVT) (37) overlaps with the single
antibody epitope that we previously identified in the F1 fragment
(NQTLEKVT RNARLVADVAG) (34). Peptide 17 developed 100%
sensitivity and 100% specificity against sera of canineVL and 100%
sensitivity human VL samples (37). All these results suggest that
the NH36 B epitopes are good candidates for immunodiagnosis
of both visceral and cutaneous leishmaniasis (33, 34, 37) and that
the F3 and F1 are good candidate for a bivalent vaccine.
Regarding the results of vaccination against the challenge by L.
chagasi (34) or L. amazonensis, the IDR response and the increase
of the proportions of lymphocytes after in vitro culture with NH36
showed similarities. In both models, the F3 vaccine was imun-
odominant, meaning that the strong contribution to protection
against cutaneous leishmaniasis by the F1 peptide is not revealed
by these variables.
Common protective effects of the F3 vaccine against the infec-
tions by L. chagasi (34) and L. amazonensis also include the
increase of: DTH response, TNF-α expression over that of IFN-
γ, levels of CD4+ and CD8+ NH36-specific splenocytes, and the
impairment of the protective efficacy by depletion of the CD4+
T cells (34), which indicate that cross-protection is mediated by
a TH1 response induced against CD4+ epitopes of F3. This is an
outstanding property of the C-terminal domain of NH36 consid-
ering the difficulties to obtain CD4+mediated immune protection
against protozoa infections (38). The F1 vaccine, on the other
hand, did not reduce the L. chagasi parasite load, despite the
induction of the IFN-γ/IL-10 expression by CD4+ T cells (34),
but reduced 57–99% of footpad lesions and parasite load, respec-
tively, in L. amazonensis infection and this decrease was impaired
by treatment with anti-CD8+ Mab. CD8 T cells have proved to
be important in infection clearance promoting localized restricted
lesions and being absent in lesions of diffuse cutaneous leishmani-
asis patients (39). Thus, the identification of an antigen promoting
a CD8 T cell-driven protection is worthy.
The in vivo depletion assay with anti-CD4 and anti-CD8 mon-
oclonal antibodies disclosed that protection against L. chagasi
infection induced by the NH36sap vaccine involved the func-
tion of CD4 and CD8+ lymphocytes (34). The CD4 protection
was mainly related to the epitopes of F3 (34). The lack of effi-
cacy of F1sap vaccine, a strong inducer of a CD8 T cell response,
against L. chagasi infection, is explained by the importance of
CD4+ T cell response in the immunosuppressive characteristic of
VL (34). Indeed a 22% decrease in the CD4+ T cell proportions
was detected in mice infected with L. chagasi while conversely, the
CD4+ levels remained stable after L. amazonensis infection. Our
results revealed that while the participation of CD4+ T cells is
responsible for the protection against L. chagasi infection (34), the
combined function of CD8+ T and CD4+ T cells is necessary
for vaccine efficacy against infection with L. amazonensis, and this
will be probably achieved by using the two peptide domains in
vaccination against cutaneous leishmaniasis.
Therefore, while the F3 peptide hosts the immunodominant
CD4+ epitopes necessary for protection against L. chagasi and L.
amazonensis, the F1 peptide exerts a co-dominance in immuno-
protection to L. amazonensis infection, which is mediated mostly
by CD8+ epitopes. Interestingly, a high affinity epitope for CD8+
T cells (YPPEFKTKL) was described in our previous work inside
the sequence of the F1 peptide (34).
Immunization with the F3 peptide exceeded in 36.73% the pro-
tective response induced by the cognate NH36 protein against
L. chagasi (34) and in 40.40% the protection induced against
L. amazonensis. These results indicate that vaccine formulations
including F3 might show the best results against visceral leishmani-
asis while a combination of F3 and F1, or a potential chimera might
be needed for protection against both visceral and cutaneous
leishmaniasis.
Our results also demonstrate the induction of long-term cross-
protection by the F3 followed by the F1 vaccine. Indeed, strong
reduction of lesion size and parasite load reduction were detected
in mice challenged 1 month after vaccination suggesting that both
vaccines are able to generate both effector and memory T cells
responsible for the immunoprotective response.
Despite the many antigens tested for vaccination in laboratory
models (7, 8) only a few are under analysis as tentative synthetic
vaccines against Leishmania (40–44). The kmp-11 (40) and the
amastigote A2 (43) contain units encoding CD8+ cytotoxic T
lymphocyte epitopes while the polyprotein Leish110f (8, 41), the
LACK158–173 peptide (42), the amastigote A2 antigen (43), and
the MML-triple fusion L. major vaccine expressed in Adenovirus
(44) trigger a Th1-biased CD4+ T cell response.
Since the NH36 function is mandatory at the early stages of
the parasite infection and is a strong phylogenetic marker (24, 25)
with significant homology to the sequences of NH of L. major
(95%) (25), L. chagasi (99%), Leishmania infantum (99%), Leish-
mania tropica (97%), Leishmania mexicana (93%), Leishmania
braziliensis (84%) (26), the achievement of high protection using
the L. donovani NH36 vaccine against the challenge by L. cha-
gasi was expected (34). The previous finding of cross-protection
against L. mexicana induced by vaccination with NH36 supported
this premise (29). Recently, the genome sequence of L. amazo-
nensis was described (35) and the presence of the gene of NH
A34480 was disclosed. We describe here that this gene shows 93%
of identity to the sequence of NH36 of L. donovani. Addition-
ally, we detected that the epitope for CD8+ T cells (34), and
one epitope for CD4+ T cells of the F1 domain are completely
conserved in L. amazonensis NH, while the other CD4+ epi-
topes of the F1 and F3 domains differ in a single amino acid,
having the rest of their sequences preserved. These results reveal
the structural basis of the demonstrated cross-immune protec-
tion induced by the L. donovani F1 and F3 vaccines in prophylaxis
to the infection by L. amazonensis, and encourage us to pursue
the development of a T cell epitope synthetic bivalent vaccine for
prophylaxis against both leishmaniasis. The C-terminal and the
N-terminal domains of NH36 could be potentially combined into
a chimera, for the bivalent vaccine. Since NH of L. donovani also
shares 68% identity with Haemophilus influenzae and 30% iden-
tity and conserved motifs with Bacillus anthracis (45) and NHs
are also found in yeasts (46) and insect cells (47), the identifi-
cation of shared NHs domains might allow the rational design
development of cross-protective subunit or synthetic vaccines for
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protection against multiple purine salvation pathway-dependent
pathogens.
To our knowledge, this is the first case of a second-generation
licensed vaccine to evolve DNA to a recombinant defined protein
formulation that might be used in a potential bivalent vaccine
against cutaneous and visceral leishmaniasis.
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